Састрави

Основна информация

  • Търговско наименование:
  • Састрави 200 mg/50 mg/200 mg филмирани таблетки x 10; x 30; x 100; x 130; x 175
  • Активна съставка:
  • L-dopa
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици

Документи

Локализация

  • Предлага се в:
  • Састрави 200 mg/50 mg/200 mg филмирани таблетки x 10; x 30; x 100; x 130; x 175
    България
  • Език:
  • български

Терапевтична информация

  • Каталог на резюме:
  • Sastravi, 200 mg/50 mg/200 mg film - coated tablets x 10; x 30; x 100; x 130; x 175

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Номер на разрешението:
  • 20140289
  • Дата Оторизация:
  • 29-09-2014
  • Последна актуализация:
  • 01-06-2018

Листовка за пациента

7-8-2018

Numient (Impax Laboratories Ireland Limited)

Numient (Impax Laboratories Ireland Limited)

Numient (Active substance: levodopa / carbidopa) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5418 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2611/T/5

Europe -DG Health and Food Safety

19-7-2018

Regulatory and procedural guideline:  Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early Parkinsonian symptoms, adopted

Regulatory and procedural guideline: Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early Parkinsonian symptoms, adopted

Critical Path Global Ltd.’s Critical Path for Parkinson’s (CPP) is a multinational consortium of the Critical Path Institute supported by Parkinson’s UK and industry. This broad collaboration of pharmaceutical companies, government agencies, academic institutions, and charities aims to accelerate the development of therapies for Parkinson’s disease (PD).

Europe - EMA - European Medicines Agency

10-7-2018

Corbilta (Orion Corporation)

Corbilta (Orion Corporation)

Corbilta (Active substance: levodopa / carbidopa / entacapone) - Centralised - Renewal - Commission Decision (2018)4468 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2785/R/15

Europe -DG Health and Food Safety